Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a) subjects on proprotein convertase subtilisin/kexin type 9 inhibitor therapy

Eur J Prev Cardiol. 2024 Jun 3;31(8):e62-e64. doi: 10.1093/eurjpc/zwae054.

Authors

Francesco Sbrana¹, Federico Bigazzi¹, Carmen Corciulo¹, Beatrice Dal Pino¹

Affiliation

¹ U.O. Lipoapheresis and Center for Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Via Moruzzi, Pisa 1-56124, Italy.

PMID: 38470832
DOI: 10.1093/eurjpc/zwae054

No abstract available

MeSH terms

Aged
Biomarkers / blood
Blood Component Removal* / adverse effects
Cardiovascular Diseases* / blood
Cardiovascular Diseases* / epidemiology
Cardiovascular Diseases* / prevention & control
Female
Humans
Hyperlipoproteinemias / blood
Hyperlipoproteinemias / complications
Hyperlipoproteinemias / diagnosis
Hyperlipoproteinemias / drug therapy
Hyperlipoproteinemias / epidemiology
Hyperlipoproteinemias / therapy
Incidence
Lipoprotein(a)* / blood
Male
Middle Aged
PCSK9 Inhibitors*
Proprotein Convertase 9 / metabolism
Serine Proteinase Inhibitors / adverse effects
Serine Proteinase Inhibitors / therapeutic use
Treatment Outcome

Substances

PCSK9 Inhibitors
Lipoprotein(a)
PCSK9 protein, human
Biomarkers
Serine Proteinase Inhibitors
LPA protein, human
Proprotein Convertase 9